ArticleJournal of clinical and experimental hematopathology : JCEH2026
Pseudoprogression of bladder extramedullary disease of multiple myeloma following the treatment with elranatamab, an anti-BCMA/CD3 bispecific antibody.
Kiyoka Ito et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.